Long-Term Pharmacokinetics of Tacrolimus in Renal Recipients
An evaluation of the effects of genetically determined variant metabolizing and transporting proteins involved in the disposition of the immunosuppressive drug tacrolimus in renal transplant recipients. In a five year follow-up study tacrolimus dose-corrected exposure changes significantly and the effect(s) of single nucleotide polymorphisms of the CYP3A4/CYP3A5 and MDR1 genes on the latter is assessed in this study.
|Study Design:||Observational Model: Defined Population
Time Perspective: Longitudinal
|Official Title:||Prospective Study of the Influence of CYP3A4/CYP3A5 and MDR1 Gene Single Nucleotide Polymorphisms on Long-Term Tacrolimus Disposition in Renal Allograft Recipients: a Five Year Follow-up Study Using Abbreviated Concentration-Time Measurements.|
|Study Start Date:||August 1999|
|Estimated Study Completion Date:||September 2005|
A 5-year pharmacokinetic follow-up study in 95 renal allograft recipients assessing tacrolimus exposure using repeated abbreviated Area-Under-the-Concentration-time (AUC) curve measurements at regular time points after grafting. The effects of the CYP3A5*1, CYP3A4*1B, MDR1 G2677T/A and C3435T single nucleotide polymorphisms on the evolution of tacrolimus disposition are studied over 5 years in order to clarify the interrelationship between CYP3A5, CYP3A4 and MDR1 genotypes, time-dependent exposure and tacrolimus-related toxicity.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00411944
|Department of Nephology and Renal Transplantation|
|Leuven, Belgium, B-3000|
|Principal Investigator:||Dirk R Kuypers, MD, PhD||Dpt Nephrology and Renal Transplantation, University Hospitals Leuven, Belgium|